Indivior Share News (INDV)

Indivior reaches settlement in litigation with US states

(Sharecast News) - Addiction treatment-focussed pharmaceuticals company Indivior announced on Monday that its subsidiary Indivior Inc has successfully reached an agreement to resolve the claims brought against it by the attorneys general of 41 US states and the District of Columbia.

Indivior settles antitrust claims in US regarding Suboxone drug

(Alliance News) - Indivior PLC on Friday said it has reached an agreement to resolve the claims brought in antitrust multi-district litigation regarding its drug Suboxone.

LONDON BROKER RATINGS: Numis starts Tristel with 'add'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Indivior emergency opioid overdose treatment approved by US FDA

(Alliance News) - Indivior PLC on Tuesday said the US Food & Drug Administration has approved its OPVEE nasal spray for the emergency treatment of opioid overdose.

Indivior's opioid addiction sprat approved by FDA

(Sharecast News) - US health regulators have approved Indivior's Opvee nasal spray treatment for opiod addiction, the company said on Tuesday.

DIRECTOR DEALINGS: Indivior division chief sells GBP1.7 million shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Wednesday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days

Indivior lifts revenue guidance, cuts profit outlook after Opiant deal

(Sharecast News) - Opioid addiction treatment maker Indivior lifted its full-year revenue guidance on Thursday but trimmed its outlook for operating profit due to costs related to the acquisition of Opiant Pharmaceuticals, as it posted a jump in first-quarter profit and revenue.

Indivior raises 2023 revenue forecast following Opiant acquisition

(Alliance News) - Indivior PLC on Thursday said net revenue increased by more than 20% in the first quarter, lifting profit, and it updated its guidance for the year following its acquisition of Opiant Pharmaceuticals Inc last month.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Indivior completes acquisition of Opiant Pharmaceuticals

Indivior PLC - North Chesterfield, Virginia-based pharmaceutical company - Completes the acquisition of Opiant Pharmaceuticals Inc. Says the acquisition will strengthen its addiction treatment and science portfolio through the addition of Opiant's late-stage assets, notably OPNT003, an investigational opioid overdose treatment.

LONDON BROKER RATINGS: Berenberg lowers Spectris; RBC cuts Direct Line

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

LONDON MARKET CLOSE: Records for FTSE and CAC but US PPI hits New York

(Alliance News) - Blue-chip benchmarks in London and Paris hit record highs on Thursday, with the FTSE 100 managing to cling to its daily gain, despite some weakness following US producer price data.

CORRECT: LONDON MARKET MIDDAY: FTSE 100 stays above 8,000

(Correcting the GBPUSD quote).

LONDON MARKET MIDDAY: FTSE 100 stays above 8,000 as Centrica jumps

(Alliance News) - Stock prices in London were higher at midday on Thursday, with London's flagship index still trading above the 8,000 mark on the back of strong performances from Centrica and Relx.